Head to Head Survey: Myokardia (MYOK) vs. Aurinia Pharmaceuticals (AUPH)

Aurinia Pharmaceuticals (NASDAQ: AUPH) and Myokardia (NASDAQ:MYOK) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Aurinia Pharmaceuticals and Myokardia, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurinia Pharmaceuticals 0 0 6 0 3.00
Myokardia 0 0 6 0 3.00

Aurinia Pharmaceuticals currently has a consensus target price of $12.00, indicating a potential upside of 124.30%. Myokardia has a consensus target price of $54.83, indicating a potential upside of 3.65%. Given Aurinia Pharmaceuticals’ higher probable upside, research analysts plainly believe Aurinia Pharmaceuticals is more favorable than Myokardia.

Institutional & Insider Ownership

28.1% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.6% of Myokardia shares are owned by institutional investors. 33.4% of Myokardia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Aurinia Pharmaceuticals and Myokardia’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aurinia Pharmaceuticals -18,089.02% -25.56% -20.72%
Myokardia -53.49% -14.92% -11.53%

Earnings & Valuation

This table compares Aurinia Pharmaceuticals and Myokardia’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aurinia Pharmaceuticals $170,000.00 2,642.59 -$23.29 million ($1.21) -4.42
Myokardia $39.20 million 48.23 -$13.15 million ($0.74) -71.49

Myokardia has higher revenue and earnings than Aurinia Pharmaceuticals. Myokardia is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Myokardia beats Aurinia Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

About Myokardia

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August


Leave a Reply

 
© 2006-2018 BBNS.